Weekly Recap: Phase 1 survival gains and HC Wainwright trims target to $6

Anixa Biosciences, Inc. (NASDAQ:ANIX) reported preliminary Phase 1 lira—cel data showing several ovarian cancer patients survived past one year as the trial continues to monitor safety and efficacy, while HC Wainwright trimmed its price target to $6.00 but kept a Buy rating.Previous Week RecapThis…